Effectiveness and Safety of LMWH Treatment in Patients With Cancer Diagnosed With Non-High-Risk Venous Thromboembolism: Turkish Observational Study (TREBECA)

Basit Öğe Kaydı
dc.authoridbenekli, mustafa/0000-0003-3184-4946
dc.authoridÖksüzoğlu Çakmak, Ömür Berna/0000-0002-2756-8646
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridElkıran, Emin Tamer/0000-0001-6681-7249
dc.authoridKOÇER, Murat/0000-0002-1541-640X
dc.authoridSevinç, Alper/0000-0002-0499-8918
dc.authoridkoçer, murat/0000-0002-1541-640X
dc.authorwosidSevinc, Alper/KFQ-6440-2024
dc.authorwosidbenekli, mustafa/AAE-4555-2020
dc.authorwosidÖksüzoğlu Çakmak, Ömür Berna/HKN-6428-2023
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidÖZASLAN, ERSİN/V-3556-2017
dc.authorwosidElkıran, Emin Tamer/ABI-8192-2020
dc.authorwosidKOÇER, Murat/GQH-4487-2022
dc.contributor.authorOzaslan, Ersin
dc.contributor.authorOzkan, Metin
dc.contributor.authorCicin, Irfan
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorKocer, Murat
dc.contributor.authorUysal, Mukremin
dc.contributor.authorOksuzoglu, Berna
dc.date.accessioned2024-08-04T20:44:18Z
dc.date.available2024-08-04T20:44:18Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractWe compared the efficacy and safety of low-molecular-weight heparins (LMWHs) in patients with cancer who are at low risk of venous thromboembolism (VTE). Patients were treated by medical oncologists in Turkey at 15 sites, where they were enrolled and followed up for a period of 12 months. Due to the study design, there was no specific treatment protocol for LMWH. Primary end points were efficacy and the time to change in VTE status. Of the included 250 patients, 239 (95.6%), 176 (70.4%), 130 (52.0%), and 91 (36.4%) completed their day 15, month 3, month 6, and month 12 visits, respectively. Number of patients treated with enoxaparin, bemiparin, and tinzaparin were 133, 112, and 5, respectively. Anticoagulant therapy provoked thrombus resolution in 1.2% and 12.7% of patients using enoxaparin and bemiparin, respectively (P = .004). Thrombus resolution was observed in 81 more patients at month 3 visit. This ratio was 35 (40.2%) of 87 and 46 (54.1%) of 85 patients administered enoxaparin and bemiparin at the third visit, respectively (P = .038). Thrombus resolution was observed in 21 more patients during month 6 visit. This ratio was 5 (7.7%) of 65 and 15 (23.4%) of 64 patients administered enoxaparin and bemiparin at the fourth visit, respectively (P = .022). The LMWH was discontinued in only 2 patients due to gastrointestinal bleeding. This pioneering study shows bemiparin is more effective than enoxaparin in thrombosis resolution and has a similar tolerability profile.en_US
dc.identifier.doi10.1177/1076029617753538
dc.identifier.endpage979en_US
dc.identifier.issn1076-0296
dc.identifier.issn1938-2723
dc.identifier.issue6en_US
dc.identifier.pmid29455568en_US
dc.identifier.scopus2-s2.0-85042207579en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage973en_US
dc.identifier.urihttps://doi.org/10.1177/1076029617753538
dc.identifier.urihttps://hdl.handle.net/11616/98162
dc.identifier.volume24en_US
dc.identifier.wosWOS:000440019200018en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofClinical and Applied Thrombosis-Hemostasisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLMWHen_US
dc.subjectVTEen_US
dc.subjectbemiparinen_US
dc.subjectenoxaparinen_US
dc.subjectthrombosisen_US
dc.subjectcanceren_US
dc.titleEffectiveness and Safety of LMWH Treatment in Patients With Cancer Diagnosed With Non-High-Risk Venous Thromboembolism: Turkish Observational Study (TREBECA)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu